Asset Details
Do you wish to reserve the book?
Evaluation of Morbidity among Human T Lymphotropic Virus Type I Carriers in Miyazaki, Japan
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evaluation of Morbidity among Human T Lymphotropic Virus Type I Carriers in Miyazaki, Japan
Do you wish to request the book?
Evaluation of Morbidity among Human T Lymphotropic Virus Type I Carriers in Miyazaki, Japan
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evaluation of Morbidity among Human T Lymphotropic Virus Type I Carriers in Miyazaki, Japan
1996
Overview
Morbidity associated with human T lymphotropic virus type I (HTLV-I) infection was investigated in a Japanese population within an area in which HTLV-I infection is endemic. Of 1824 subjects enrolled in the Miyazaki Cohort Study between November 1984 and May 1991, 500 (27.4%) were seropositive for HTLV-I antibodies. As expected from previous studies, HTLV-I positivity appeared to be associated with baseline history of anemia (adjusted odds ratio [OR] = 1.3; 95% confidence interval [CI] = 0.99–1.7) and kidney disease (OR = 1.6; 95% CI = 0.91–2.9); a positive association also was noted for asthma in men (OR = 3.4; 95% CI = 1.2–9.8). Unanticipated findings included a relationship between HTLV-I infection and cardiac disease history (OR = 1.4; 95% CI = 0.94–2.2); HTLV-I carriers also were more likely to have an abnormal electrocardiogram at baseline (OR = 1.5; 95% CI = 1.2–1.9). Furthermore, an apparent protective effect for ulcers (OR = 0.62; 95% CI = 0.40–0.95) and diabetes (OR = 0.49; 95% CI = 0.22–1.1) was observed. HTLV-I infection may modify the risk of specific disease outcomes by altering host immune function.
Publisher
The University of Chicago Press,University of Chicago Press
